Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Evaxion Biotech Q4 EPS $(0.16) Beats $(1.60) Estimate, Sales $73.00K

Author: Benzinga Newsdesk | March 27, 2024 07:34am
Evaxion Biotech (NASDAQ:EVAX) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(1.60) by 90 percent. This is a 94.48 percent increase over losses of $(2.90) per share from the same period last year. The company reported $73.00 thousand in sales this quarter.

Posted In: EVAX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist